Dendritic cells require multidrug resistance protein 1 (ABCC1) transporter activity for differentiation

The Journal of Immunology : Official Journal of the American Association of Immunologists
Rieneke van de VenRik J Scheper

Abstract

Dendritic cells (DC) express the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and multidrug resistance protein 1 (MRP1; ABCC1). Functionally, both these transporters have been described to be required for efficient DC and T cell migration. In this study, we report that MRP1 activity is also crucial for differentiation of DC. Inhibition of MRP1, but not P-glycoprotein, transporter activity with specific antagonists during in vitro DC differentiation interfered with early DC development. Impaired interstitial and Langerhans DC differentiation was characterized by 1) morphological changes, reflected by dropped side scatter levels in flow cytometric analysis and 2) phenotypic changes illustrated by maintained expression of the monocytic marker CD14, lower expression levels of CD40, CD86, HLA-DR, and a significant decrease in the amount of cells expressing CD1a, CD1c, and Langerin. Defective DC differentiation also resulted in their reduced ability to stimulate allogeneic T cells. We identified the endogenous CD1 ligands sulfatide and monosialoganglioside GM1 as MRP1 substrates, but exogenous addition of these substrates could not restore the defects caused by blocking MRP1 activity during DC differentiation. Altho...Continue Reading

References

Nov 11, 1976·Biochimica Et Biophysica Acta·R L Juliano, V Ling
Jan 1, 1992·The American Journal of Physiology·M HeijnP L Jansen
Sep 15, 1988·International Journal of Cancer. Journal International Du Cancer·R J ScheperJ Lankelma
Mar 1, 1980·Proceedings of the National Academy of Sciences of the United States of America·E L ReinherzS F Schlossman
Jan 1, 1995·Annual Review of Biochemistry·M T Heemels, H Ploegh
Nov 15, 1993·Biochemical and Biophysical Research Communications·M GarrigosS Orlowski
Jan 1, 1996·Advances in Experimental Medicine and Biology·A H MerrillR T Riley
Feb 1, 1997·European Journal of Immunology·F ChapuisJ C Gluckman
Jun 17, 1998·Proceedings of the National Academy of Sciences of the United States of America·G J RandolphW A Muller
Aug 13, 1998·Journal of the National Cancer Institute·A J SmithP Borst
Jun 3, 2000·Annual Review of Immunology·J BanchereauK Palucka
Jun 17, 2000·Biochimica Et Biophysica Acta·P BorstA van Helvoort
Aug 17, 2000·Journal of the National Cancer Institute·P BorstJ Wijnholds
Jul 21, 2001·The Biochemical Journal·R J RaggersG van Meer
Feb 2, 2002·The Journal of Immunology : Official Journal of the American Association of Immunologists·Anouk B SchroeijersRik J Scheper
Mar 21, 2002·Nature Reviews. Cancer·Michael M GottesmanSusan E Bates
Apr 17, 2002·The Journal of Experimental Medicine·A ShamshievG De Libero
Apr 24, 2002·The Journal of Immunology : Official Journal of the American Association of Immunologists·Claudia C SombroekTanja D de Gruijl
Jan 22, 2003·Advanced Drug Delivery Reviews·Alfred H Schinkel, Johan W Jonker
Feb 21, 2003·European Journal of Immunology·Vania ManolovaGennaro De Libero
Sep 3, 2003·European Journal of Biochemistry·Antonios KlokouzasStephen B Hladky
Dec 20, 2003·Cancer Immunology, Immunotherapy : CII·Theresa L Whiteside, Christine Odoux

❮ Previous
Next ❯

Citations

Sep 12, 2009·Journal of Leukocyte Biology·Rieneke van de VenRik J Scheper
Mar 28, 2012·The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences·Naoki InuiKingo Chida
Dec 12, 2012·Transplant International : Official Journal of the European Society for Organ Transplantation·Inés LlaudóNúria Lloberas
Oct 25, 2017·Parasite Immunology·K Donskow-ŁysoniewskaM Doligalska
Mar 21, 2020·Frontiers in Oncology·Kianna Robinson, Venkataswarup Tiriveedhi
Oct 22, 2008·American Journal of Physiology. Lung Cellular and Molecular Physiology·Masakata YoshiokaKazuhisa Takahashi
May 21, 2008·The Journal of Immunology : Official Journal of the American Association of Immunologists·Grzegorz WoszczekJames H Shelhamer
Jan 15, 2009·International Journal of Cancer. Journal International Du Cancer·Lena OevermannChristoph A Ritter
Jan 8, 2011·Fundamental & Clinical Pharmacology·Amélie MoreauOlivier Fardel
Feb 9, 2011·Expert Opinion on Drug Metabolism & Toxicology·Neill James Liptrott, Andrew Owen
Apr 13, 2019·Current Topics in Medicinal Chemistry·Niraj Kumar JhaRituraj Niranjan
Dec 7, 2007·Pflügers Archiv : European journal of physiology·Raphael C ValenteMárcia A M Capella
Jun 19, 2008·Experimental Dermatology·Claudia SkazikJens Malte Baron
Jun 4, 2010·Journal of Clinical Psychopharmacology·Sung Hee LeeMin Goo Lee
Mar 30, 2011·Immunology and Cell Biology·Rieneke van de VenTanja D de Gruijl
Jul 10, 2007·Respiratory Research·Margaretha van der DeenHuib A Kerstjens
Jun 17, 2009·Hypertension·João Marcos A DelouMárcia A M Capella
Oct 17, 2018·Nature Communications·Shilpi ChandraMitchell Kronenberg
Aug 25, 2009·Trends in Immunology·Rieneke van de VenTanja D de Gruijl

❮ Previous
Next ❯

Related Concepts

Related Feeds

Adult Stem Cells

Adult stem cells reside in unique niches that provide vital cues for their survival, self-renewal, and differentiation. They hold great promise for use in tissue repair and regeneration as a novel therapeutic strategies. Here is the latest research.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.